<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691038</url>
  </required_header>
  <id_info>
    <org_study_id>2018-08-013</org_study_id>
    <nct_id>NCT03691038</nct_id>
  </id_info>
  <brief_title>Comparison of Conventional Dose Regimen and New Dose Regimen of Pregabalin</brief_title>
  <official_title>Comparison of Conventional Flexible Dose Regimen of Pregabalin and New Flexible Dose Regimen of Pregabalin Using Low Dose: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to propose a new flexible dose regimen starting from 75mg using
      the low dose pregabalin 25 mg and 50 mg comparing the side effect and compliance with the
      conventional flexible dose regimen staring from 150mg using the pregabalin 75mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregabalin has been shown to be effective as a first-line medication for neuropathic pain but
      it appears to have several side effects such as dizziness, drowsiness, and edema, which
      lowers compliance with medications. A way to reduce side effects is the flexible dose
      regimen, which reaches the target dose to treat the drug. The proposed flexible dose regimen
      is a regimen that begins with twice the prevalence of 75 mg. However, dizziness is the most
      common side effect up to 20% in conventional flexible dose regimen. Therefore, the aim of
      this study was to propose a new flexible regimen starting at a dose less than the existing
      dose and to compare compliance with pregabaline according to both methods
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>discontinuation of medication</measure>
    <time_frame>After 7 weeks of prescription</time_frame>
    <description>the portion of patients discontinuing medication</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Pain, Neuropathic</condition>
  <arm_group>
    <arm_group_label>Pregabalin 75mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients who were prescribed according to the conventional flexible dose regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pregabalin 25mg,50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients who were prescribed according to the new flexible dose regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 75mg bid</intervention_name>
    <description>Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.</description>
    <arm_group_label>Pregabalin 75mg bid</arm_group_label>
    <other_name>Conventional regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 25mg, 50mg</intervention_name>
    <description>Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg</description>
    <arm_group_label>pregabalin 25mg,50mg</arm_group_label>
    <other_name>New regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pain score NRS ≥3 Patients complaining of neuropathic pain (except neuropathic pain
             due to chemotherapy)

          -  Adult patients aged 19 to 85 years

          -  Patients who pre-agreed to the study

        Exclusion Criteria:

          -  Patients complaining of severe pain (NRS ≥ 8)

          -  Creatinine clearance of &lt;30 mL / min, the liver was more than 3 times normal

          -  Patients complaining of dizziness, patients with definite orthostatic hypotension

          -  Pregnant or lactating patients

          -  Patients who previously experienced side effects after administration pregabalin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Hyun Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyoung-Ho Ryu Ryu, MD</last_name>
    <phone>82-2-2001-1376</phone>
    <email>drkhryu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sung Hyun Lee, MD</last_name>
    <phone>82-2-2001-2323</phone>
    <email>4321hoho@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyoung-Ho Ryu, M.D.</last_name>
      <phone>+82-2-2001-1376</phone>
      <email>drkhryu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Kyoung-Ho Ryu, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

